A strategic tie-up between the UK-based company creator and builder, Arix Bioscience PLC, and the China-focused Fosun International Ltd., announced Feb. 19, will give rise to the two partners working together to invest in, and create, new companies that will develop innovative clinical therapies in a broad range of therapeutic areas, with an emphasis on the Chinese market.
China is the world's second-largest pharmaceutical market, and judging from the burgeoning presence of Chinese executives at biotech investment meetings...








